[1
]
From the Respiratory Therapeutic Area Unit, GlaxoSmithKline, Research Triangle Park,
NC (H.G.O., L.E.K., S.W.Y.); Johns Hopkins Asthma and Allergy Center, Baltimore (M.C.L.);
Respiratory Medicine Unit, Nuffield Department of Medicine, University of Oxford,
Oxford (I.D.P.), and Clinical Statistics, GlaxoSmithKline, Stockley Park, Middlesex
(O.N.K.) - both in the United Kingdom; the Department of Respiratory Medicine, Ghent
University Hospital, Ghent, Belgium (G.G.B.); the Lung Centre, Institute for Heart
and Lung Health, Vancouver, BC, Canada (J.M.F.); the Department of Clinical and Experimental
Medicine, University of Parma, Parma, Italy (A.C.); and Assistance Publique-Hôpitaux
de Paris, Département Hospitalo-Universitaire Thorax Innovation, Service de Pneumologie,
Hôpital Bicêtre, Université Paris-Sud, and INSERM Unité Mixte de Recherche 999, Le
Kremlin-Bicêtre (M.H.), and Unités Mixtes de Recherche INSERM Unité 1067 Centre Nationale
de la Recherche Scientifique 7733, Aix-Marseille Université, Department of Respiratory
Diseases and Clinical Investigation Center, Assistance Publique-Hôpitaux de Marseille,
Hôpital Nord, Marseille (P.C.) - both in France.